Mukka Proteins manufactures and exports fish meal, fish oil, and fish soluble paste used primarily as high-protein ingredients for aquaculture and poultry feed. The company is also expanding into sustainable insect-based proteins produced from Black Soldier Fly larvae for the animal nutrition market.
The company lacks a wide moat as evidenced by thin net margins (3.7%) and a significant decline in revenue and profits in FY25, suggesting a lack of pricing power. While regulatory barriers like MPEDA moratoriums on new capacity provide some protection for existing players, the business remains highly sensitive to cyclical fish catch volumes and commodity price fluctuations.
Management utilized IPO proceeds primarily for working capital and investment in an insect protein subsidiary. While they have maintained a consistent dividend-free policy to reinvest in growth, the recent failed preferential issue and high debt-to-equity ratio (1.56) suggest aggressive but sometimes inconsistent financing strategies.
The business succumbed to a classic commodity trap where high leverage met a cyclical downturn. The negative cash conversion cycle and high debt-to-equity ratio created a liquidity crunch when fish catch volumes remained depressed for consecutive seasons. As revenue and profits continued the double-digit slide observed in FY25, the company lacked the pricing power to pass on costs, and the heavy interest burden from its 1.56 debt-to-equity ratio eventually forced a fire sale or massive dilution to stay afloat, proving that a business dependent on nature's whims and thin margins is a fragile vessel.
RichFakir rates Mukka Proteins Ltd's business quality as mediocre — 40/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Mukka Proteins Ltd is trading about 60% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Mukka Proteins Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Mukka Proteins Ltd's fair value is about ₹18 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →